David Wallington, MD

@azhangmd @kpnorcal @YaleRadOnc @RU_RadOnc @ARRO_org This is great! Is there a way to download a version the watermark or with it in a different location?

Update! CNS Brain Metastasis 2025 is now available at andrewzhangmd.com to download for free! @kpnorcal @YaleRadOnc @RU_RadOnc @ARRO_org

.@PatrickOhMD presented findings at #ASTRO25 on how easing lung V5 constraints may improve cardiac dosimetry and further minimize risk to vulnerable organs. @SmilowCancer @ASTRO_org Learn More ⬇️ poster.astro.org/astro/2025/67t…

Thank you for highlighting our work! Further details to come in the manuscript. Would not be possible without the brilliant minds of @jryckman3 @gwalls89 @KrishanJethwa @HenryParkMD and Joshua Scott!

An important study presented at #ASTRO25 demonstrates the deleterious effects of using V5 lung constraints for thoracic radiation therapy treatment planning, and hopefully puts an end to this sad era in our field when some of us thought it mattered poster.astro.org/astro/2025/67t…

🚨Updated data from the FLAME trial🚨 @JCO_ASCO 🔥Focally boosting intraprostatic MRI lesions improved biochemical DFS🔥 👉71% v 86% at 10 years 👉HR 0.40 🔗shorturl.at/6uRLC @urotoday @PCFnews @UrologyTimes @renalandurology

Our lab at @YaleMed seeks #postdocs with in vivo expertise to pioneer research at the intersection of tissue remodeling & aging. Work with us to uncover immunological & vascular drivers of ovarian aging, applying single-cell, spatial omics, and ML!

“A surrogate endpoint is something a patient didn’t know was important until a doctor said it was” — @adamcifu

Excited to share our recent publication reporting clinical outcomes of brachytherapy for endometrial cancer pts with narrow vaginal anatomy. Our regimen of 10 Gy x 3 fx to the cylinder surface was well-tolerated and achieved excellent local control! brachyjournal.com/article/S1538-…

@HenryParkMD @YaleMed @YaleCancer @YaleRadOnc Well deserved, congrats Henry!!

Grateful to be promoted to full professor @YaleMed! I truly appreciate all the support along the way, including from countless mentors, colleagues, letter writers, trainees, friends, and family, especially my parents and wife. I plan to pay it forward! @YaleCancer @YaleRadOnc

⚡️ New multicenter data on SBRT for primary renal cell carcinoma (RCC): - 98% LC at 1 year, 96% at 5 years - Median OS: 58 months - Preserved renal function & low severe toxicity A promising noninvasive option for inoperable RCC #KidneyCancer #Oncology @_ShankarSiva @dr_alimuhammad @UliSchick @stephane_supiot @CiroFranzese1 @MartaScorsetti @DrAndreiFodor @NicosiaMd @alongi_filippo @MarioTerlizziFR @PBlanchardMD @BaudeJeremy @mcmbarthoulot @David__Pasquier sciencedirect.com/science/articl…

@YaleRadOnc @ZacharyBWhiteII @StanfordRO_Res Fantastic lecture by @ZacharyBWhiteII and great to share some New Haven pizza after!

Residents from two of the oldest #RadOnc programs in the country supporting each other! We had a great evening coming out to see @ZacharyBWhiteII (@StanfordRO_Res) give an inspiring talk at Yale, reminding us of the importance of persistence, patience, and purpose in medicine🔥

Seminars in Radiation Oncology shares "The Role of Radiotherapy in Lymphoma Patients Undergoing CAR T Therapy: Past, Present, and Future" by Dr. Wallington @dg_wallington, Dr. Imber @brandon_imber, Dr. Scordo @MScordoMD, Dr. Robinson @YaleCancer sciencedirect.com/science/articl…

Congratulations to our PGY2 resident @tomypatrich presenting his research at #ACRO2025 on quality of life outcomes in high-risk prostate cancer patients treated with an SBRT boost!

Another in-service exam in the books ✅

Research from @YaleHematology shows great potential for radiation therapy to improve CAR T efficacy & toxicity, identify which pts may be most likely to benefit & confirm proposed clinical benefits. pubmed.ncbi.nlm.nih.gov/39672646/ @SmilowCancer @YaleMed @YNHH @YaleRadOnc @dg_wallington

Just returned home from a scheduled exam by my RADIATION ONCOLOGIST Dr. Biagioli & he gave me good news as he said my progress from 30 radiation treatments has been excellent. Now will celebrate at a neighbor’s CHRISTMAS bash . 🙏🙏🙏 have worked.

@5_utr @SuyogCancer It will be interesting to see if curves cross with more follow up, definitely a good concept though and invasive numbers quite low in both arms.

@5_utr @SuyogCancer It looks like the invasive cancers are just being diagnosed incidentally at lumpectomy so it makes sense the incidence over 2 years is a little higher with surgery? Also per protocol tx only about 55% in the surgery arm - quite low for a NI study?

‼️ COMET trial: Active monitoring vs surgery for low risk DCIS 2 year cumulative ipsilateral invasive cancer: 4.2% in monitoring vs 5.9% w/ surgery An argument many women w/ low grade DCIS, especially older women with comorbidities, should be left alone @SuyogCancer #SABCS24

Presented at #SABCS24: Interim results from the EUROPA trial: Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer thelancet.com/journals/lanon…